All In Biotech

Drug Trial Radar · NCT00659789

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

A Phase II, Randomized, Double-blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV-1 Who Have Maintained an Adequate Response to ART

Last checked: Nov 19, 2026Latest source record: Feb 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

137

Actual

Start

Aug 2008

Primary completion

Jun 2010

Study completion Jun 2011

Sponsor

Lead sponsor
Bionor Immuno ASIndustry
Sponsor type
Industry
First posted
Apr 16, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Current management of HIV infection includes anti-retroviral therapy (ART). ART cannot cure the infection, making it a life-long treatment that requires sustained patient compliance and imposes significant individual and societal financial burdens on healthcare services. Furthermore, ART side effects often require medication that increases the inconveniences and financial burdens of HIV management. Of further concern is the emergence of viruses resistant to ART that can result in treatment failure. ART-free periods could provide substantial benefit. Vacc-4x is a peptide-based HIV immunotherapy that is proposed for prolongation of ART-free periods. The purpose of this study is to determine whether Vacc-4x immunotherapy can give safe ART-free period.

Conditions

  • HIV I Infection

Interventions

  • Vacc-4xDrug

    Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

  • Sterile waterDrug

    Sterile water is used in place of Vacc-4x and in place of Leukine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Who Require Resumption of ART Between the Interruption of ART at Week 28 and End of Study at Week 52.Time frame: From Week 28 to Week 52

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • UCLA CARE Center

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UC Davis Medical Center

    Sacramento, California

  • University of Miami School of Medicine

    Miami, Florida

  • Northwestern University Division of Infectious Diseases

    Chicago, Illinois

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Klinik I für Innere Medizin Klinikum Der Universität zu Köln

    Cologne, Germany

  • ifi - Studien und Projekte GmbH, an der Asklepios-Klinik St. George

    Hamburg, Germany

  • Universitätsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • EPIMED GmbH

    Berlin, State of Berlin, Germany

  • Charité Universitätsmedizin Berlin

    Berlin, State of Berlin, Germany

  • Istituto San Raffaele

    Milan, Italy

  • Hospital Germans Trias i Pujol

    Badalona, Spain

  • Hospital Clinic i Provincial

    Barcelona, Spain

  • Unidad de VIH, Hospital de Bellvitge, Calle Feixa Llarga s/n, Hospitalet de Llobregat.

    Barcelona, Spain

  • Brighton and Sussex University Hospital, HIV/GUM Research, Elton John Centre

    Brighton, United Kingdom

  • Chelsea and Westminster Hospital

    London, United Kingdom

  • Harrison Wing St Thomas' Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.